State Street Corp Mei Pharma, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.65 $668,871 - $1.04 Million	-1,592,551 Reduced 81.71%	356,455 $216,000
Q1 2022 May 16, 2022	BUY	$0.54 - $2.74 $33,389 - $169,419	61,832 Added 3.28%	1,949,006 $1.17 Million
Q4 2021 Feb 14, 2022	SELL	$2.33 - $3.37 $17,731 - $25,645	-7,610 Reduced 0.4%	1,887,174 $5.04 Million
Q3 2021 Nov 15, 2021	BUY	$2.52 - $2.99 $58,166 - $69,015	23,082 Added 1.23%	1,894,784 $5.23 Million
Q2 2021 Aug 16, 2021	BUY	$2.6 - $3.65 $264,123 - $370,788	101,586 Added 5.74%	1,871,702 $5.33 Million

Q1 2021 May 17, 2021	SELL	$2.73 - $4.5 $136,778 - $225,459	-50,102 Reduced 2.75%	1,770,116 $6.07 Million
Q4 2020 Feb 16, 2021	BUY	$2.6 - $3.32 $28,103 - $35,885	10,809 Added 0.6%	1,820,218 $4.81 Million
Q3 2020 Nov 10, 2020	SELL	$2.46 - $4.27 $84,446 - $146,580	-34,328 Reduced 1.86%	1,809,409 $5.65 Million
Q2 2020 Aug 14, 2020	BUY	$1.45 - $4.3 $464,672 - $1.38 Million	320,464 Added 21.04%	1,843,737 $7.62 Million
Q1 2020 May 11, 2020	BUY	$0.75 - $2.55 $1.14 Million - $3.88 Million	1,523,273 New	1,523,273 $2.45 Million

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $373M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.